Industry stakeholders see cloud-based collaboration as next step in FDA’s digital health overhaul

Oracle’s cloud bravado masks its database despair
Digital health stakeholders say a cloud-based platform would provide a collaborative approach to the FDA's new regulatory paradigm. (iStockphoto)

Pleased with the Food and Drug Administration’s (FDA) focus on reimagining digital health oversight, industry stakeholders have some thoughts about how the agency should move those efforts forward.

One of those ideas includes the creation of an “integrated online collaboration capability,” a cloud-based platform where manufacturers could submit applications and allow other participating companies to access information on approvals and adverse events.

That approach was fleshed out in a report released by Deloitte this week based on a two-day session with industry stakeholders, startups, patient advocacy groups and FDA regulators. A potential framework emerged from that discussion that emphasized the need for regulators to provide a clear regulatory pathway that uses a risk-based approach and the ability to analyze real-world data from multiple sources.

Free Daily Newsletter

Like this story? Subscribe to FierceHealthcare!

The healthcare sector remains in flux as policy, regulation, technology and trends shape the market. FierceHealthcare subscribers rely on our suite of newsletters as their must-read source for the latest news, analysis and data impacting their world. Sign up today to get healthcare news and updates delivered to your inbox and read on the go.

The ideal solution, the report concluded, would be the creation of a secure cloud-based platform that would house the FDA’s regulatory development kit, the new software precertification program and data from a variety of stakeholders, all of which would be accessible by the entire ecosystem. While individual companies would have access to their own proprietary information and application process, broader data sharing on approvals, user adoption and product quality would help organizations navigate the new paradigm.

RELATED: FDA finalizes new guidance to support medical device innovation and ease burden of software updates

“As SaMD [Software as a Medical Device] technology becomes cheaper, more accessible and more sophisticated, it is likely to play an increasingly important role in healthcare delivery, personalized medicin, and medical research,” the analysts wrote. “To realize its full benefit, however, regulation of these devices will need to radically change to accommodate new SaMD manufacturers and the technology’s rapid evolution, and to harness SaMD’s ability to capture RWD to create a collaborative, innovative SaMD community.”

RELATED: FDA’s Scott Gottlieb wants to use funding boost to create a Center of Excellence on Digital Health

Whether the FDA will adopt those suggestions remains to be seen. Last month, FDA Commissioner Scott Gottlieb said if the agency receives an additional $473 million outlined under President Donald Trump’s budget proposal, he plans to create a new Center of Excellence on Digital Health that would oversee the agency’s new regulatory paradigm and include a new cybersecurity unit.

Under Gottlieb, the FDA has made significant changes to the way it plans to regulate digital health tools, launching a new precertification pilot program that includes some of the country’s largest tech companies. Gottlieb has said the agency will remain focused on digital health throughout the year.  

Suggested Articles

Consumers could have saved billions in 2017 if price variation for certain services was addressed, according to a new report. 

Officials announced on Friday a proposal to remove healthcare protections for transgender patients and women seeking to terminate pregnancies.

The American Medical Informatics Association says ONC's proposed rule doesn't go far enough to put patients and providers in the driver's seat…